Literature DB >> 18971638

Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen.

Oliver D Staples1, Jonathan J Hollick, Johanna Campbell, Maureen Higgins, Anna R McCarthy, Virginia Appleyard, Karen E Murray, Lee Baker, Alastair Thompson, Sebastien Ronseaux, Alexandra M Z Slawin, David P Lane, Nicholas J Westwood, Sonia Lain.   

Abstract

A robust p53 cell-based assay that exploits p53's function as a transcription factor was used to screen a small molecule library and identify bioactive small molecules with potential antitumor activity. Unexpectedly, the majority of the highest ranking hit compounds from this screen arrest cells in mitosis and most of them impair polymerization of tubulin in cells and in vitro. One of these novel compounds, JJ78:1, was subjected to structure-activity relationship studies and optimized leading to the identification of JJ78:12. This molecule is significantly more potent than the original hit JJ78:1, as it is active in cells at two-digit nanomolar concentrations and shows clear antitumor activity in a mouse xenograft model as a single agent. The effects of nocodazole, a well established tubulin poison, and JJ78:12 on p53 levels are remarkably similar, supporting that tubulin depolymerization is the main mechanism by which JJ78:12 treatment leads to p53 activation in cells. In summary, these results identify JJ78:12 as a potential cancer therapeutic, demonstrate that screening for activators of p53 in a cell-based assay is an effective way to identify inhibitors of mitosis progression and highlights p53's sensitivity to alterations during mitosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971638      PMCID: PMC2709220          DOI: 10.4161/cc.7.21.6982

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

Review 1.  The p53 tumor suppressor participates in multiple cell cycle checkpoints.

Authors:  Luciana E Giono; James J Manfredi
Journal:  J Cell Physiol       Date:  2006-10       Impact factor: 6.384

2.  Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2006-05-01       Impact factor: 4.534

Review 3.  Update on tubulin-binding agents.

Authors:  Gerhardt Attard; Alastair Greystoke; Stan Kaye; Johann De Bono
Journal:  Pathol Biol (Paris)       Date:  2006-03

4.  Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B.

Authors:  P Smart; E B Lane; D P Lane; C Midgley; B Vojtesek; S Laín
Journal:  Oncogene       Date:  1999-12-02       Impact factor: 9.867

5.  Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Authors:  Natalia Issaeva; Przemyslaw Bozko; Martin Enge; Marina Protopopova; Lisette G G C Verhoef; Maria Masucci; Aladdin Pramanik; Galina Selivanova
Journal:  Nat Med       Date:  2004-11-21       Impact factor: 53.440

6.  DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.

Authors:  J P Blaydes; T R Hupp
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

7.  Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis.

Authors:  Z N Demidenko; S Kalurupalle; C Hanko; C-u Lim; E Broude; M V Blagosklonny
Journal:  Oncogene       Date:  2008-05-12       Impact factor: 9.867

Review 8.  The use of esters as prodrugs for oral delivery of beta-lactam antibiotics.

Authors:  L Mizen; G Burton
Journal:  Pharm Biotechnol       Date:  1998

9.  Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.

Authors:  Ashutosh Tripathi; Micaela Fornabaio; Glen E Kellogg; John T Gupton; David A Gewirtz; W Andrew Yeudall; Nina E Vega; Susan L Mooberry
Journal:  Bioorg Med Chem       Date:  2007-12-04       Impact factor: 3.641

10.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more
  9 in total

Review 1.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 2.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

Review 3.  MDM2-p53 pathway in hepatocellular carcinoma.

Authors:  Xuan Meng; Derek A Franklin; Jiahong Dong; Yanping Zhang
Journal:  Cancer Res       Date:  2014-12-04       Impact factor: 12.701

4.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

Review 5.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 6.  Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.

Authors:  Anubhav Jain; Saurabh Bundela; Ram P Tiwari; Prakash S Bisen
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

7.  Phenformin as prophylaxis and therapy in breast cancer xenografts.

Authors:  M V C L Appleyard; K E Murray; P J Coates; S Wullschleger; S E Bray; N M Kernohan; S Fleming; D R Alessi; A M Thompson
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

Review 8.  Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Authors:  David J Olivos; Lindsey D Mayo
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923

Review 9.  Small molecule activators of the p53 response.

Authors:  Marcus J G W Ladds; Sonia Laín
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.